This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


Steven Chamow
President at Chamow & Associates, Inc.


Steven Chamow, Ph.D., has over 30 years of experience in biopharmaceutical product development and is a recognized expert in monoclonal antibodies and Fc fusion proteins.  Since 2008, he has served as president of Chamow & Associates, Inc., a consulting group working with biotechnology companies to design and implement development strategies for new therapeutic products.  His efforts have contributed to the development of four marketed biologics (Avastin, Natrecor, Vectibix, Zadaxin).  Previously, he was Senior Vice President, CMC, at Intradigm Corporation, a private biopharmaceutical company focused on developing RNAi therapeutics.  In other executive roles, he served as Vice President, Process Sciences, at Genitope Corporation and at Abgenix, Inc., where he built the company’s process sciences department and helped to lead the design and construction of Abgenix’ award-winning production facility in Fremont, CA (sold by Amgen to Boehringer-Ingelheim to become its first North American production facility).  Before Abgenix, he was Director of Biopharmaceutical Development at Scios, Inc., and as a scientist and senior scientist in process development at Genentech, Inc..  Dr. Chamow was educated at the University of California (UC Santa Cruz, B.A. in biology; UC Davis, Ph.D. in biochemistry), and completed postdoctoral training at the National Institutes of Health.  He is author or co-author of more than 50 scientific publications and patents and co-editor of two books.

Agenda Sessions

  • Capture of CH1-containing bispecific antibodies: An alternative to Protein A

  • Live Speakers Discussion Forum


Speakers at this event